Objective to observe the effect and toxicity of rituximab and CHOP regimen (R-CHOP) in the treatment of initially diagnosed diffuse large B-cell lymphoma.
目的观察利妥昔单抗联合CHOP方案(R - CHOP)治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
Determined that patients with diffuse large B cell lymphoma had high serum levels of miR-21, which associated with increased relapse-free survival 3. Around the same time, Mitchell et al.
Lawrie等人证实，弥漫性大B细胞淋巴瘤的病人的血清mir - 21水平很高，后者与增高的不复发存活率密切相关。
Conclusions the treatment effectiveness in newly diagnosed diffuse large-B-cell lymphoma in the elderly has been improved by an individual treatment plan according to evidence-based methods.
结论采用循证医学的方法为初治的老年弥漫性大B细胞淋巴瘤患者制定化疗方案可有效提高治疗效果。
Conclusions Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
结论弥漫性大B细胞性淋巴瘤治疗后生存期可通过肿瘤微环境中的免疫细胞、纤维化、血管形成的差异而影响。
Conclusions Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
结论弥漫性大B细胞性淋巴瘤治疗后生存期可通过肿瘤微环境中的免疫细胞、纤维化、血管形成的差异而影响。
应用推荐